MOH's Medicaid focus, dual-eligible expansion and stronger share gains make it stand out against UNH in managed care.
UnitedHealth (UNH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
UnitedHealth (UNH) reported earnings 30 days ago. What's next for the stock?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Mizuho raised its price target on UnitedHealth Group (NYSE:UNH | UNH Price Prediction) to $440 from $410 and kept an Outperform rating on the managed care leader.
Wall Street analysts are projecting that healthcare giant UnitedHealth (NYSE: UNH) stock is likely to see further momentum over the next 12 months.
UNH is under the spotlight after Berkshire Hathaway's 13F reveals it exited its entire stake, sparking surprise selling and fresh scrutiny on headwinds.
The Oracle of Omaha may not be calling the shots anymore, but Berkshire Hathaway's stock picks can still move markets.
Shares of UnitedHealth Group fell over 2% on Monday after Berkshire Hathaway disclosed that it had exited its entire position in the health insurer during the first quarter, ending a brief but closely watched investment. The healthcare giant's stock had recently staged a strong rebound, posting its seventh consecutive weekly gain after rising about 4% last week.
For years, investors treated Warren Buffett's Berkshire Hathaway ( NYSE:BRK-A | BRK-A Price Prediction )( NYSE:BRK-B ) as the market's ultimate “follow-the-smart-money” signal.
UnitedHealth Group Incorporated (UNH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
UnitedHealth Group is rated a slim Buy following a 59% recovery from March lows, driven by strong Q1 results and a favorable 2027 CMS rate decision. Q1 revenue reached $111.72B with EPS of $7.23, prompting management to raise full-year EPS guidance to over $18.25 and authorize a $2B+ Q2 buyback. UNH's vertical integration justifies its premium valuation, but DOJ antitrust risks and PBM regulatory changes could challenge its integrated business model.